Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 131
Filtrar
1.
Int J Mol Sci ; 22(18)2021 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-34576213

RESUMO

Diabetes mellitus is a chronic metabolic disease characterized by disturbances in carbohydrate, protein, and lipid metabolism, often accompanied by oxidative stress. Diabetes treatment is a complicated process in which, in addition to the standard pharmacological action, it is necessary to append a comprehensive approach. Introducing the aspect of non-pharmacological treatment of diabetes allows one to alleviate its many adverse complications. Therefore, it seems important to look for substances that, when included in the daily diet, can improve diabetic parameters. Magnolol, a polyphenolic compound found in magnolia bark, is known for its health-promoting activities and multidirectional beneficial effects on the body. Accordingly, the goal of this review is to systematize the available scientific literature on its beneficial effects on type 2 diabetes and its complications. Taking the above into consideration, the article collects data on the favorable effects of magnolol on parameters related to glycemia, lipid metabolism, or oxidative stress in the course of diabetes. After careful analysis of many scientific articles, it can be concluded that this lignan is a promising agent supporting the conventional therapies with antidiabetic drugs in order to manage diabetes and diabetes-related diseases.


Assuntos
Compostos de Bifenilo/farmacologia , Complicações do Diabetes/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Lignanas/metabolismo , Animais , Glicemia/análise , Nefropatias Diabéticas/tratamento farmacológico , Oftalmopatias/tratamento farmacológico , Homeostase , Humanos , Hipoglicemiantes/farmacologia , Inflamação , Lignanas/farmacologia , Metabolismo dos Lipídeos , Magnolia , Camundongos , Estresse Oxidativo , Casca de Planta , Polifenóis/química , Resultado do Tratamento
2.
Exp Eye Res ; 189: 107829, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31605685

RESUMO

Approximately 30-70% of the existing and new chemical entities exhibit poor aqueous solubility. For topical ocular delivery, drug molecules need to possess both hydrophilic and lipophilic nature to enable absorption through the aqueous tear layer and permeation through the corneal lipophilic barrier. To overcome the aqueous solubility related issues, various techniques such as solid dispersion, particle size reduction, cyclodextrin complexation, co-solvency, prodrug, derivatization, and salt formation are being explored in the healthcare sector. Cyclodextrin inclusion complexation techniques have been established by several pharmaceutical industries for systemic administration allowing a transition from the lab to the clinics. Though cyclodextrins are exploited in ocular drug delivery, there are prevailing concerns regarding its absorption enhancing capacity and mechanism, retention at the ocular surfaces and, irritation and toxicity profiles. In the present review, the efforts taken by various research groups to address the concerns of using cyclodextrin and its derivatives in ocular therapeutics are summarized. Also, considerations and utility of cyclodextrin systems in fabricating newer formulations such as contact lens, inserts, and implants have been discussed in the review.


Assuntos
Ciclodextrinas/administração & dosagem , Oftalmopatias/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Humanos , Soluções Oftálmicas/administração & dosagem , Resultado do Tratamento
3.
Biochemistry (Mosc) ; 83(12): 1563-1574, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30878031

RESUMO

Visual system is at high risk of iatrogenic damage. Laser ocular surgery, the use of powerful illumination devices in diagnostics and surgical treatment of eye diseases, as well as long surgeries under general anesthesia provoke the development of chronic degenerative changes in eye tissues, primarily in the cornea and the retina. Despite the existence of approaches for prevention and treatment of these complications, the efficacy of these approaches is often limited. Here, we review the mechanisms of iatrogenic damage to eye tissues at the cellular and biochemical levels. It is well recognized that oxidative stress is one of the main factors hindering regeneration of eye tissues after injuries and, thereby, aggravating iatrogenic eye disorders. It is accompanied by the downregulation of low-molecular-weight antioxidants and antioxidant enzymes, as well as changes in the expression and redox status of proteins in the damaged tissue. In this regard, antioxidant therapy, in particular, the use of highly effective mitochondria-targeted antioxidants such as SkQ1, is considered as a promising approach to the prevention of iatrogenesis. Recent findings indicate that the most efficient protection of eye tissues from the iatrogenic injury is achieved by preventive use of these antioxidants. In addition to preventing corneal and retinal cell death induced by oxidative stress, SkQ1 contributes to the restoration of innate antioxidant defense of these tissues and suppresses local inflammatory response. Since the timing of routine medical manipulations is usually known in advance, iatrogenic damage to the ocular tissues can be successfully prevented using mitochondria-targeted therapy.


Assuntos
Oftalmopatias , Doença Iatrogênica , Animais , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Oftalmopatias/tratamento farmacológico , Oftalmopatias/etiologia , Oftalmopatias/patologia , Oftalmopatias/prevenção & controle , Humanos , Doença Iatrogênica/prevenção & controle , Mitocôndrias/efeitos dos fármacos
4.
Adv Gerontol ; 31(2): 300-305, 2018.
Artigo em Russo | MEDLINE | ID: mdl-30080340

RESUMO

The article examines the indicators of physical and economic accessibility of pharmaceutical care to patients of older age groups with visual impairment from the perspective of the patient-centered approach. The motives of consumers' behavior when choosing pharmacy organizations and ophthalmic preparations are revealed. The estimation of the consumers' satisfaction with the location of pharmacy organizations and the available in them assortment of medicines for treatment and prevention of eye diseases is given. The consumer perception of the market price of ophthalmic drugs on the Russian pharmaceutical market is represented. It is established that the revealed indicators of accessibility provide an opportunity for a wide choice of medicines for treatment and prevention of eye diseases, taking into account modern methods of pharmacotherapy, individual characteristics of the disease, consumer preferences and financial capabilities of consumers, providing practical implementation of the concept of patient- centered pharmaceutical care for ophthalmic patients of older age groups.


Assuntos
Oftalmopatias/tratamento farmacológico , Assistência Centrada no Paciente , Assistência Farmacêutica/organização & administração , Idoso , Comportamento do Consumidor , Humanos , Federação Russa
5.
Br J Dermatol ; 176(2): 465-471, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27861741

RESUMO

BACKGROUND: Rosacea is currently treated according to subtypes. As this does not adequately address the spectrum of clinical presentation (phenotypes), it has implications for patient management. The ROSacea COnsensus panel was established to address this issue. OBJECTIVES: To incorporate current best treatment evidence with clinical experience from an international expert panel and establish consensus to improve outcomes for patients with rosacea. METHODS: Seventeen dermatologists and three ophthalmologists reached consensus on critical aspects of rosacea treatment and management using a modified Delphi approach. The panel voted on statements using the responses 'strongly disagree', 'disagree', 'agree' or 'strongly agree'. Consensus was defined as ≥ 75% 'agree' or 'strongly agree'. All voting was electronic and blinded. RESULTS: The panel agreed on phenotype-based treatments for signs and symptoms presenting in individuals with rosacea. First-line treatments were identified for individual major features of transient and persistent erythema, inflammatory papules/pustules, telangiectasia and phyma, underpinned by general skincare measures. Multiple features in an individual patient can be simultaneously treated with multiple agents. If treatment is inadequate given appropriate duration, another first-line option or the addition of another first-line agent should be considered. Maintenance treatment depends on treatment modality and patient preferences. Ophthalmological referral for all but the mildest ocular features should be considered. Lid hygiene and artificial tears in addition to medications are used to treat ocular rosacea. CONCLUSIONS: Rosacea diagnosis and treatment should be based on clinical presentation. Consensus was achieved to support this approach for rosacea treatment strategies.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Rosácea/tratamento farmacológico , Algoritmos , Consenso , Cosmecêuticos/uso terapêutico , Quimioterapia Combinada , Oftalmopatias/tratamento farmacológico , Humanos , Higiene da Pele/métodos , Protetores Solares/uso terapêutico , Resultado do Tratamento
6.
Hautarzt ; 67(10): 774-779, 2016 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-27631412

RESUMO

Autoimmune bullous diseases are characterized by intraepidermal or subepidermal autoantibody deposition that leads to blisters and secondary erosion. Mucous membranes are frequently affected in pemphigus vulgaris and always involved in cicatricial and mucosal pemphigoid. Mucosal lesions are detected less frequently in patients with bullous pemphigoid or epidermolysis bullosa acquisita. The diagnosis of autoimmune bullous disorders is based on determination of the subtype of autoantibodies bound in the skin and the clinical picture. Treatment is based on immunosuppression related to the type of disease and severity of the mucosal symptoms. Ocular involvement in mucosal pemphigoid and pemphigus vulgaris requires systemic treatment.


Assuntos
Imunossupressores/uso terapêutico , Mucosa/patologia , Penfigoide Mucomembranoso Benigno/diagnóstico , Penfigoide Mucomembranoso Benigno/tratamento farmacológico , Pênfigo/diagnóstico por imagem , Pênfigo/tratamento farmacológico , Diagnóstico Diferencial , Medicina Baseada em Evidências , Oftalmopatias/diagnóstico , Oftalmopatias/tratamento farmacológico , Humanos , Doenças da Boca/diagnóstico , Doenças da Boca/tratamento farmacológico , Resultado do Tratamento
7.
Mol Cell Biochem ; 388(1-2): 173-83, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24311110

RESUMO

A number of nutritional supplements containing antioxidants are advertised for better vision health. Do they benefit the average consumer? The literature was examined for the effectiveness of antioxidants for human eye health, and for the intricacies in collection of such evidence. The following diseases were considered: cataract, glaucoma, age-related macular degeneration (AMD), retinopathy, retinitis pigmentosa, eye infections, and uveitis. The literature indicates that antioxidant supplements plus lutein have a reasonable probability of retarding AMD. For glaucoma, such supplements were ineffectual in some studies but useful in others. In some studies, antioxidant rich fruits and vegetables were also useful for protection against glaucoma. For diabetic retinopathy, antioxidant supplements may have a small benefit, if any, but only as an adjunct to glycemic control. In very high-risk premature retinopathy and retinitis pigmentosa, antioxidant supplements may be beneficial but those with excess Vitamin E should be avoided. For cataract, there is no evidence for an advantage of such nutritional supplements. However, lubricant drops containing N-acetylcarnosine may be helpful in initial stages of the disease. For eye infections and other causes of uveitis, antioxidants have not been found useful. We recommend that a diet high in antioxidant rich foods should be developed as a habit from an early age. However, when initial signs of vision health deterioration are observed, the appropriate nutritional supplement products may be recommended but only to augment the primary medical treatments.


Assuntos
Antioxidantes/uso terapêutico , Oftalmopatias/dietoterapia , Oftalmopatias/tratamento farmacológico , Visão Ocular/efeitos dos fármacos , Cegueira/prevenção & controle , Catarata/dietoterapia , Catarata/tratamento farmacológico , Suplementos Nutricionais , Infecções Oculares/dietoterapia , Infecções Oculares/tratamento farmacológico , Glaucoma/dietoterapia , Glaucoma/tratamento farmacológico , Humanos , Luteína/uso terapêutico , Degeneração Macular/dietoterapia , Degeneração Macular/tratamento farmacológico , Espécies Reativas de Oxigênio , Retinose Pigmentar/dietoterapia , Retinose Pigmentar/tratamento farmacológico , Vitaminas/uso terapêutico
8.
Digestion ; 86 Suppl 1: 28-35, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23051724

RESUMO

Inflammatory bowel disease (IBD) is a systemic disease associated with a large number of extraintestinal manifestations (EIM). EIM are present in 15-20% of patients with ulcerative colitis and in 20-40% of patients with Crohn's disease. The management of EIM is best provided by a multidisciplinary team, which includes specialists in the affected organ systems with training in the treatment of IBD. Therapeutic strategy is often empirical. This is explained by the paucity of randomized-controlled studies for the specific treatment of EIM in IBD and by the fact that treatment models are based on extrapolation from patients with similar conditions but without IBD. For most EIM, the mainstay of therapy is the treatment of the underlying active IBD. However, some EIM such as axial arthritis, pyoderma gangrenosum, uveitis and primary sclerosing cholangitis run a clinical course independent of IBD activity and need specific therapy (e.g. TNF antagonists in ankylosing spondylitis and skin manifestations). This review summarizes the conventional and novel (e.g. anti-TNF) treatment modalities, and the therapeutic implications for the management of extraintestinal symptoms in IBD, in order to assist clinicians in optimizing treatment strategies for IBD patients with EIM.


Assuntos
Artrite/tratamento farmacológico , Colangite Esclerosante/tratamento farmacológico , Oftalmopatias/tratamento farmacológico , Doenças Inflamatórias Intestinais/complicações , Osteoporose/tratamento farmacológico , Dermatopatias/tratamento farmacológico , Tromboembolia Venosa/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Anticoagulantes/uso terapêutico , Artrite/etiologia , Conservadores da Densidade Óssea/uso terapêutico , Colagogos e Coleréticos/uso terapêutico , Colangite Esclerosante/etiologia , Oftalmopatias/etiologia , Humanos , Imunossupressores/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Osteoporose/etiologia , Dermatopatias/etiologia , Ácido Ursodesoxicólico/uso terapêutico , Tromboembolia Venosa/etiologia , Tromboembolia Venosa/prevenção & controle
9.
Nippon Ganka Gakkai Zasshi ; 116(2): 86-94, 2012 Feb.
Artigo em Japonês | MEDLINE | ID: mdl-22509696

RESUMO

PURPOSE: To examine the efficacy and safety of nepafenac ophthalmic suspension 0.1% on postoperative inflammation and eye pain with intraocular surgery, other than cataract surgery. PATIENTS AND METHODS: Patients scheduled to undergo vitreous surgery, trabeculectomy, laser iridotomy, laser trabeculoplasty and laser posterior capsulotomy were investigated in a multicenter, open-label study. RESULTS: The total rate of patients cured in all the intraocular surgery methods was 85.6% (95/111), and that of the patients who were pain free was 91.0% (101/111). The rate cured by vitreous surgery was 80.4% (45/56), by laser iridotomy 93.3% (14/15) and by laser posterior capsulotomy was 94.6% (35/37). The rate of patients free from pain following vitreous surgery was 85.7% (48/56), laser iridotomy 100.0% (15/15) and by laser posterior capsulotomy was 94.6% (35/37). A total of 23 adverse events were reported in 22 patients (19.6%). Allergic conjunctivitis was observed in one patient (0.9%) as an adverse event, in which the relationship cannot be denied. This allergic conjunctivitis was mild and resolved after treatment. CONCLUSION: Nepafenac ophthalmic suspension 0.1% is considered safe and efficious not only following cataract surgery but also for postoperative inflammation and eye pain in intraocular surgery.


Assuntos
Benzenoacetamidas/administração & dosagem , Oftalmopatias/tratamento farmacológico , Dor Ocular/tratamento farmacológico , Procedimentos Cirúrgicos Oftalmológicos , Dor Pós-Operatória/tratamento farmacológico , Fenilacetatos/administração & dosagem , Adulto , Idoso , Oftalmopatias/prevenção & controle , Dor Ocular/prevenção & controle , Feminino , Humanos , Inflamação , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Dor Pós-Operatória/prevenção & controle , Resultado do Tratamento
10.
Parasitol Int ; 86: 102481, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34688883

RESUMO

Dirofilariasis is an emerging zoonosis caused by nematodes of the genus Dirofilaria, most often D. repens and D. immitis. The main final hosts and reservoirs of pathogens are dogs. The intermediate hosts and vectors of infection are female mosquitoes (Culicidae). Human is an accidental host in which the parasite does not usually mature. Over the past 20 years, the range of Dirofilaria spp. in Europe has expanded. We present an unusual case of multifocal dirofilariasis of mixed subcutaneous-ocular course caused by D. repens in a 52-year-old Polish patient who was probably infected in Spain or Croatia, where she stayed one year before the onset of symptoms. Surgical removal of the nematodes followed by treatment with Ivermectin in a single dose of 1200 µg and Doxycycline 200 mg daily for 7 days resulted in complete recovery. We believe that all cases of human dirofilariasis, especially in countries where the disease is not frequent at present, should be registered for epidemiological purposes. Moreover, due to the widening of the range of D. repens and D. immitis occurrence and the possibility of atypical courses of infection with both nematodes, diagnostics should include the species identification of the parasite.


Assuntos
Dirofilaria repens/isolamento & purificação , Dirofilariose/diagnóstico , Oftalmopatias/diagnóstico , Dermatopatias/diagnóstico , Animais , Antiparasitários/administração & dosagem , Croácia , Dirofilariose/tratamento farmacológico , Dirofilariose/parasitologia , Dirofilariose/cirurgia , Doxiciclina/administração & dosagem , Oftalmopatias/tratamento farmacológico , Oftalmopatias/parasitologia , Oftalmopatias/cirurgia , Feminino , Humanos , Ivermectina/administração & dosagem , Pessoa de Meia-Idade , Polônia , Dermatopatias/tratamento farmacológico , Dermatopatias/parasitologia , Dermatopatias/cirurgia , Espanha , Viagem , Resultado do Tratamento
11.
J Immunol Res ; 2021: 2324400, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34966823

RESUMO

PURPOSE: To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. METHODS: We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled trials, cohort studies, case controls, and case reports. RESULTS: Seven studies, including 11 patients, were included in the final systematic analysis. Of the 11 patients, there were 5 cases of juvenile idiopathic arthritis- (JIA-) associated uveitis, 1 case of rheumatoid arthritis- (RA-) associated keratitis, 1 case of RA-associated scleritis, 1 case of psoriasis-associated conjunctivitis, 2 cases of noninfectious scleritis, and 1 case of uveitis with suspected autoimmune disease. None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy. Irrespective of whether they were suffering from uveitis, scleritis, or other types of ocular inflammation, all 11 patients showed an improvement to JAK inhibitors without significant side effects. Different types of JAK inhibitors might be associated with different responses when used to treat ocular inflammation. CONCLUSIONS: JAK inhibitors may represent an alternative treatment option for patients with autoimmune ocular inflammation.


Assuntos
Doenças Autoimunes/tratamento farmacológico , Oftalmopatias/tratamento farmacológico , Inflamação/tratamento farmacológico , Inibidores de Janus Quinases/uso terapêutico , Animais , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/etiologia , Gerenciamento Clínico , Suscetibilidade a Doenças , Oftalmopatias/diagnóstico , Oftalmopatias/etiologia , Humanos , Inflamação/diagnóstico , Inflamação/etiologia , Inibidores de Janus Quinases/administração & dosagem , Inibidores de Janus Quinases/efeitos adversos , Terapia de Alvo Molecular , Resultado do Tratamento
12.
Am Fam Physician ; 81(2): 137-44, 2010 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-20082509

RESUMO

Red eye is the cardinal sign of ocular inflammation. The condition is usually benign and can be managed by primary care physicians. Conjunctivitis is the most common cause of red eye. Other common causes include blepharitis, corneal abrasion, foreign body, subconjunctival hemorrhage, keratitis, iritis, glaucoma, chemical burn, and scleritis. Signs and symptoms of red eye include eye discharge, redness, pain, photophobia, itching, and visual changes. Generally, viral and bacterial conjunctivitis are self-limiting conditions, and serious complications are rare. Because there is no specific diagnostic test to differentiate viral from bacterial conjunctivitis, most cases are treated using broad-spectrum antibiotics. Allergies or irritants also may cause conjunctivitis. The cause of red eye can be diagnosed through a detailed patient history and careful eye examination, and treatment is based on the underlying etiology. Recognizing the need for emergent referral to an ophthalmologist is key in the primary care management of red eye. Referral is necessary when severe pain is not relieved with topical anesthetics; topical steroids are needed; or the patient has vision loss, copious purulent discharge, corneal involvement, traumatic eye injury, recent ocular surgery, distorted pupil, herpes infection, or recurrent infections.


Assuntos
Medicina de Família e Comunidade/métodos , Ceratoconjuntivite/diagnóstico , Ceratoconjuntivite/tratamento farmacológico , Atenção Primária à Saúde/métodos , Algoritmos , Antibacterianos/uso terapêutico , Blefarite/tratamento farmacológico , Blefarite/terapia , Queimaduras Químicas/tratamento farmacológico , Queimaduras Químicas/terapia , Doenças da Córnea/tratamento farmacológico , Doenças da Córnea/terapia , Úlcera da Córnea/tratamento farmacológico , Úlcera da Córnea/terapia , Diagnóstico Diferencial , Síndromes do Olho Seco/tratamento farmacológico , Síndromes do Olho Seco/terapia , Endoftalmite/tratamento farmacológico , Endoftalmite/terapia , Queimaduras Oculares/tratamento farmacológico , Queimaduras Oculares/terapia , Oftalmopatias/diagnóstico , Oftalmopatias/tratamento farmacológico , Oftalmopatias/terapia , Corpos Estranhos no Olho/tratamento farmacológico , Corpos Estranhos no Olho/terapia , Infecções Oculares/tratamento farmacológico , Infecções Oculares/terapia , Traumatismos Oculares/tratamento farmacológico , Traumatismos Oculares/terapia , Glaucoma/diagnóstico , Glaucoma/tratamento farmacológico , Glucocorticoides/uso terapêutico , Humanos
13.
J Sci Food Agric ; 90(1): 2-12, 2010 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-20355006

RESUMO

Lutein and zeaxanthin are members of the oxygenated carotenoids found particularly in egg yolks and dark-green leafy vegetables. A great deal of research has focused on their beneficial roles in eye health. The present article summarises the current literature related to the bioactivity of these carotenoids, emphasising their effects and possible mechanisms of action in relation to human eye health. Available evidence demonstrates that lutein and zeaxanthin are widely distributed in a number of body tissues and are uniquely concentrated in the retina and lens, indicating that each has a possible specific function in these two vital ocular tissues. Most of epidemiological studies and clinical trials support the notion that lutein and zeaxanthin have a potential role in the prevention and treatment of certain eye diseases such as age-related macular degeneration, cataract and retinitis pigmentosa. The biological mechanisms for the protective effects of these carotenoids may include powerful blue-light filtering activities and antioxidant properties. Although most studies point towards significant health benefits from lutein and zeaxanthin, further large-scale randomised supplementation trials are needed to define their effects on ocular function in health and disease.


Assuntos
Antioxidantes/farmacologia , Oftalmopatias/tratamento farmacológico , Olho/efeitos dos fármacos , Luteína/farmacologia , Xantofilas/farmacologia , Antioxidantes/metabolismo , Antioxidantes/uso terapêutico , Oftalmopatias/prevenção & controle , Humanos , Cristalino/metabolismo , Luz , Luteína/metabolismo , Luteína/uso terapêutico , Retina/metabolismo , Distribuição Tecidual , Xantofilas/metabolismo , Xantofilas/uso terapêutico , Zeaxantinas
14.
Z Rheumatol ; 69(5): 419-24, 2010 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-20517612

RESUMO

Connective tissue diseases and systemic vasculitides are commonly associated with ocular manifestations, which can lead to severe complications and even blindness. The present review article describes these ocular manifestations, their signs and symptoms and possible treatment options for Sjoegren's syndrome, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APLS), as well as those of giant cell arteritis/cranial arteritis, ANCA-associated vasculitides and Behçet's disease. Additionally, possible ocular adverse effects of antimalarial agents are described.


Assuntos
Doenças do Tecido Conjuntivo/diagnóstico , Oftalmopatias/diagnóstico , Vasculite/diagnóstico , Corticosteroides/administração & dosagem , Corticosteroides/efeitos adversos , Produtos Biológicos/administração & dosagem , Produtos Biológicos/efeitos adversos , Cegueira/etiologia , Cegueira/prevenção & controle , Doenças do Tecido Conjuntivo/tratamento farmacológico , Diagnóstico Diferencial , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Oftalmopatias/tratamento farmacológico , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Assistência de Longa Duração , Prednisolona/administração & dosagem , Prednisolona/efeitos adversos , Vasculite/tratamento farmacológico
15.
Oftalmologia ; 53(4): 83-90, 2009.
Artigo em Romano | MEDLINE | ID: mdl-20361657

RESUMO

UNLABELLED: Controlled release of drugs on ocular level is an important care for modern pharmacology. New studies targets are medical ophthalmic products with prolonged action (controlled release, target release). The hydrogel is an important segment in these studies. The purpose of this study is to assess a monolithic thermosensible hydrogel for releasing a certain medical product. MATERIAL AND METHOD: We used several materials for making thermosensible ophthalmic inserts that were processed (hydrogel synthesis, establish the inflation degree, hydrogel drug inclusion, establish the kinetics of in vitro drug releasing, in vivo studies). RESULTS: The study show that MA-G and PNIPAm basis hydrogel is a smart one that have the ability to collapse on a temperature closed to the physiological one, the result is the drug release in a desired doses. The hydrogel is perfectly tolerated, an experimental study prove that. CONCLUSIONS: Controlled release of active drug that are highly adequate to have a clinical response is based on small doses, without adverse effects. Is a target release.


Assuntos
Portadores de Fármacos/química , Portadores de Fármacos/síntese química , Implantes de Medicamento , Oftalmopatias/tratamento farmacológico , Hidrogel de Polietilenoglicol-Dimetacrilato/química , Hidrogel de Polietilenoglicol-Dimetacrilato/síntese química , Química Farmacêutica , Humanos , Resultado do Tratamento
16.
Oxid Med Cell Longev ; 2019: 9783429, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30891116

RESUMO

Oxidative stress and inflammation play a critical role in the initiation and progression of age-related ocular abnormalities as cataract, glaucoma, diabetic retinopathy, and macular degeneration. Therefore, phytochemicals with proven antioxidant and anti-inflammatory activities, such as carotenoids and polyphenols, could be of benefit in these diseases. We searched PubMed and Web of Science databases for original studies investigating the benefits of different carotenoids and polyphenols in age-related ophthalmic diseases. Our results showed that several polyphenols (such as anthocyanins, Ginkgo biloba, quercetin, and resveratrol) and carotenoids (such as lutein, zeaxanthin, and mezoxanthin) have shown significant preventive and therapeutic benefits against the aforementioned conditions. The involved mechanisms in these findings include mitigating the production of reactive oxygen species, inhibiting the tumor necrosis factor-α and vascular endothelial growth factor pathways, suppressing p53-dependent apoptosis, and suppressing the production of inflammatory markers, such as interleukin- (IL-) 8, IL-6, IL-1a, and endothelial leucocyte adhesion molecule-1. Consumption of products containing these phytochemicals may be protective against these diseases; however, adequate human data are lacking. This review discusses the role and mechanisms of polyphenols and carotenoids and their possible synergistic effects on the prevention and treatment of age-related eye diseases that are induced or augmented by oxidative stress and inflammation.


Assuntos
Envelhecimento/patologia , Carotenoides/uso terapêutico , Oftalmopatias/tratamento farmacológico , Polifenóis/uso terapêutico , Animais , Oftalmopatias/prevenção & controle , Humanos , Estresse Oxidativo
17.
Res Social Adm Pharm ; 15(8): 943-948, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30737195

RESUMO

BACKGROUND: There has been a trend in the past five years in Jordan for ophthalmic anticholinergic preparations to be misused or abused. This is done mainly to experience mental altering effects such as mood changes, euphoria or hallucinations. Such products are mostly obtained from community pharmacies without a prescription. OBJECTIVES: This study aimed to observe the requests of ophthalmic preparations in community pharmacies in Amman, Jordan, and evaluating the most popular and frequently requested ophthalmic drops suspected of abuse. Also, it aimed to describe the current methods that Jordanian community pharmacists use to manage such requests. METHODS: A prospective cross-sectional observational study was conducted between November 2016 and January 2017 at sixteen different community pharmacies in Amman. All ophthalmic products requested were observed during this period. RESULTS: A total of 140 ophthalmic product requests for 130 customers were observed. Dry eye was the most common complaint for which the customer requested the medication (n = 30, 23.1%) and direct self-medication (ie-requesting the product by name), was the most frequent method of purchase (n = 63, 48.5%). In 19 cases (14.6%), product requests were suspected to be for non-medical (ie-abuse) purposes. Most of the suspected cases were for Pentolate® (n = 11, 57.9%), whereas 7 were for Prisoline® (36.8%) and 1 for Naphcon-A® (5.3%). The majority of observed cases were for products requested without a prescription (n = 16, 84.2%), and in 12 cases out of which, sale was refused (63.2%). CONCLUSION: More effort and enforcement of pharmacy regulation for safe dispensing is needed to reduce the abuse of ophthalmic products. Educating pharmacists and ophthalmologists would help raise awareness and control the type of drug abuse.


Assuntos
Soluções Oftálmicas/administração & dosagem , Farmácias/estatística & dados numéricos , Transtornos Relacionados ao Uso de Substâncias , Adulto , Compostos de Benzalcônio , Oftalmopatias/tratamento farmacológico , Feminino , Humanos , Jordânia , Masculino , Pessoa de Meia-Idade , Nafazolina , Feniramina , Adulto Jovem
18.
J Feline Med Surg ; 21(1): 35-45, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30763152

RESUMO

PRACTICAL RELEVANCE: Systemic hypertension is common in older cats and can result in damage to organs with a rich arteriolar supply such as the eyes, kidneys, myocardium and brain. Hypertensive disease in these organs is known as target organ damage (TOD). Disease in the eye resulting from hypertension is the most easily identifiable form of TOD and can often be the reason the cat is presented to the veterinarian. Routine blood pressure measurement and fundic examination allows cats with hypertensive ocular lesions to be detected early in the course of the disease, when the lesions have the best chance of responding to treatment. CLINICAL CHALLENGES: Detecting early evidence of TOD in the fundus requires a veterinarian to be competent in recognising lesions associated with mild hypertensive disease, as well as the more easily recognised advanced lesions that frequently result in impaired vision and blindness. AUDIENCE: This review is written for all veterinarians who treat cats. It provides information and images to facilitate and guide veterinarians performing fundoscopy in cats, in particular in those over 7 years of age, with the aim of diagnosing hypertensive ocular lesions when they are present. EQUIPMENT: The clinical manifestations of hypertensive ocular disease can be detected non-invasively with inexpensive equipment. A summary of the equipment available for general practitioners to perform fundoscopy is provided. EVIDENCE BASE: This is a comprehensive review of the literature on hypertensive ocular disease in cats. The author has also included images of hypertensive ocular lesions taken in general practice to highlight the variety of lesions that can be detected.


Assuntos
Doenças do Gato/diagnóstico , Oftalmopatias/veterinária , Hipertensão/veterinária , Animais , Determinação da Pressão Arterial/veterinária , Doenças do Gato/tratamento farmacológico , Gatos , Diagnóstico Precoce , Oftalmopatias/diagnóstico , Oftalmopatias/tratamento farmacológico , Humanos , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Exame Físico/métodos , Exame Físico/veterinária
19.
BMJ Case Rep ; 12(2)2019 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-30755424

RESUMO

Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterised by the appearance of erythematous plaques and papules with overlying non-follicular pinpoint pustules. Drugs are the cause of AGEP in approximately 90% of cases. The most common causes include anti-infective agents (aminopenicillins, quinolones, antibacterial sulfonamides and terbinafine), antimalarials and diltiazem. To the best of our knowledge, to date there has only been one report of hydrochlorothiazide-induced AGEP. There has never been a case report of losartan-induced AGEP. Here, we present a case of AGEP that is the second case purportedly caused by hydrochlorothiazide.


Assuntos
Pustulose Exantematosa Aguda Generalizada/patologia , Anti-Infecciosos/efeitos adversos , Oftalmopatias/tratamento farmacológico , Hidroclorotiazida/efeitos adversos , Impetigo/tratamento farmacológico , Pustulose Exantematosa Aguda Generalizada/tratamento farmacológico , Administração Tópica , Idoso de 80 Anos ou mais , Anti-Infecciosos/uso terapêutico , Betametasona/uso terapêutico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Oftalmopatias/patologia , Feminino , Glucocorticoides/uso terapêutico , Humanos , Hidroclorotiazida/uso terapêutico , Impetigo/patologia , Metoprolol/uso terapêutico , Resultado do Tratamento
20.
Rev Prat ; 58(4): 353-7, 2008 Feb 29.
Artigo em Francês | MEDLINE | ID: mdl-18506971

RESUMO

Red eye in children is a common consultation purpose. Mostly benign, this sign may also cause visual impairment. We differentiate three kinds of red eye: localised, diffused and perikeratic injection. The last one must be recognized because of its association with severe ocular diseases. Diagnosis must be sure and treatment has to be efficient to not pertubate childrens visual development. Unfortunately, physical examination on children is not always easy. Consultation with an ophthalmologist is justified if a doubt remains, in case of chronic pathology or resistance to first intention treatment.


Assuntos
Oftalmopatias , Fatores Etários , Algoritmos , Blefarite/diagnóstico , Blefarite/terapia , Criança , Conjuntivite/diagnóstico , Conjuntivite/tratamento farmacológico , Conjuntivite/etiologia , Conjuntivite/terapia , Doenças da Córnea/diagnóstico , Doenças da Córnea/terapia , Diagnóstico Diferencial , Emergências , Oftalmopatias/diagnóstico , Oftalmopatias/tratamento farmacológico , Oftalmopatias/terapia , Infecções Oculares/diagnóstico , Traumatismos Oculares/diagnóstico , Traumatismos Oculares/terapia , Medicina de Família e Comunidade , Glaucoma/diagnóstico , Humanos , Lactente , Recém-Nascido , Ceratite/diagnóstico , Ceratite/etiologia , Ceratite/terapia , Ceratite Herpética/diagnóstico , Soluções Oftálmicas , Oftalmologia , Doenças Orbitárias/diagnóstico , Doenças Orbitárias/cirurgia , Encaminhamento e Consulta , Uveíte/diagnóstico , Acuidade Visual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA